A recent letter in JCO discusses whether patients with locally advanced rectal cancer need adjuvant chemotherapy.
A decision model finds that the higher cost of new sequencing methods is justified by their clinical benefits.
[Biomarkers in Cancer] Cluster of differentiation 151 (CD151) functions at various stages of cancer, including metastatic cascade and primary tumor growth, reinforcing the importance of CD151 as a target in oncology.
Multigene panel technology is gaining favor, but tests are outpacing the molecular-epidemiological evidence base and models for patient counseling.
From Oncology Nurse Advisor
Sign Up for Free e-newsletters
Cancer Therapy Advisor Articles
- Do Patients with Locally Advanced Rectal Cancer Benefit from Adjuvant Chemotherapy?
- Tumor Infiltrating Lymphocytes Play Prognostic Role in Triple Negative Breast Cancer
- Surgical Margin Status Has No Effect on Prostate Cancer Survival
- VCD Regimen Preferable as Induction for Newly Diagnosed Multiple Myeloma
- CD151—A Striking Marker for Cancer Therapy
- Vitamin D Levels and Risk for Pancreatic Cancer
- Anti-PD-L1 Antibody Demonstrates Antitumor Activity in Triple-Negative Breast Cancer
- New Screening Method May Identify Twice As Many Women with Ovarian Cancer
- Head and Neck Cancers Treatment Regimens
- Role of Genetic Mutations in Metastatic Castrate-Resistant Prostate Cancer Treatment
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|